FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants

Influenza viruses (IVs) cause substantial global morbidity and mortality. Given the limited range of licensed antiviral drugs and their reduced efficacy due to resistance mutations, repurposing FDA-approved kinase inhibitors as fast-tracked host-targeted antivirals is an attractive strategy. We iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Meineke, Robert, Stelz, Sonja, Busch, Maximilian, Werlein, Christopher, Kühnel, Mark, Jonigk, Danny, Rimmelzwaan, Guus F., Elbahesh, Husni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034449/
https://www.ncbi.nlm.nih.gov/pubmed/36968089
http://dx.doi.org/10.1016/j.isci.2023.106309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034449/
https://www.ncbi.nlm.nih.gov/pubmed/36968089
http://dx.doi.org/10.1016/j.isci.2023.106309

Ejemplares similares